Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours

BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1–14 of 3-week cycles. R...

Descripción completa

Detalles Bibliográficos
Autores principales: Medley, L, Morel, A N, Farrugia, D, Reed, N, Hayward, N, Davies, J M, Kirichek, O, Thakker, R V, Talbot, D C
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2011
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3068509/
https://www.ncbi.nlm.nih.gov/pubmed/21386841
http://dx.doi.org/10.1038/bjc.2011.76
Descripción
Sumario:BACKGROUND: This study sought to determine the safety of single agent capecitabine, a pro-drug of 5FU, in patients with metastatic non-pancreatic neuroendocrine tumours (NETs). METHODS: Multicentre phase II, first-line study design. Oral capecitabine was administered on days 1–14 of 3-week cycles. RESULTS: Treatment was safe and well tolerated. Common toxicities were diarrhoea and fatigue. CONCLUSION: The study provides evidence to support the use of capecitabine as a substitute for infusional 5FU in the management of NETs.

Ejemplares similares